- Home
- JPC vs NAMS Comparison
JPC vs NAMS Comparison
Compare JPC & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- NAMS
- Stock Information
- Founded
- JPC 2003
- NAMS 2019
- Country
- JPC United States
- NAMS Netherlands
- Employees
- JPC N/A
- NAMS N/A
- Industry
- JPC Investment Managers
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- NAMS Health Care
- Exchange
- JPC Nasdaq
- NAMS Nasdaq
- Market Cap
- JPC 2.5B
- NAMS 2.7B
- IPO Year
- JPC N/A
- NAMS N/A
- Fundamental
- Price
- JPC $8.08
- NAMS $25.00
- Analyst Decision
- JPC
- NAMS Strong Buy
- Analyst Count
- JPC 0
- NAMS 9
- Target Price
- JPC N/A
- NAMS $41.00
- AVG Volume (30 Days)
- JPC 998.5K
- NAMS 786.8K
- Earning Date
- JPC 01-01-0001
- NAMS 08-06-2025
- Dividend Yield
- JPC 7.57%
- NAMS N/A
- EPS Growth
- JPC N/A
- NAMS N/A
- EPS
- JPC N/A
- NAMS N/A
- Revenue
- JPC N/A
- NAMS $64,006,000.00
- Revenue This Year
- JPC N/A
- NAMS N/A
- Revenue Next Year
- JPC N/A
- NAMS $73.09
- P/E Ratio
- JPC N/A
- NAMS N/A
- Revenue Growth
- JPC N/A
- NAMS 762.15
- 52 Week Low
- JPC $5.94
- NAMS $14.06
- 52 Week High
- JPC $7.36
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- JPC 53.83
- NAMS 59.65
- Support Level
- JPC $8.05
- NAMS $23.69
- Resistance Level
- JPC $8.13
- NAMS $25.90
- Average True Range (ATR)
- JPC 0.04
- NAMS 1.29
- MACD
- JPC -0.00
- NAMS -0.06
- Stochastic Oscillator
- JPC 45.00
- NAMS 80.69
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.